Attitudes of health care professionals toward pharmacogenetic testing (Q37881950)

24 August 2017

1 reference

title

Attitudes of health care professionals toward pharmacogenetic testing (English)

1 reference

24 August 2017

1 reference

3

Rami A Mahfouz

1 reference

24 August 2017

Nathalie K Zgheib

1

1 reference

24 August 2017

Thalia Arawi

series ordinal

2

1 reference

24 August 2017

Ramzi Sabra

series ordinal

4

1 reference

24 August 2017

publication date

1 April 2011

1 reference

Molecular Diagnosis and Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

15

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

115-122

1 reference

An introduction to genes, genomes and disease.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Pharmacogenetics in Europe: barriers and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Why should we bother? Ethical and social issues in individualized medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Moving towards individualized medicine with pharmacogenomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Estimation of the warfarin dose with clinical and pharmacogenetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

HLA-B*5701 screening for hypersensitivity to abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Review of an Article: The international Warfarin Pharmacogenetics Consortium (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. NEJM 360 (8): 753-64.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Pharmacogenetics: ethical problems and solutions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Pharmacogenetics and ethical considerations: why care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Education, ethics and knowledge deficits in clinical pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Context, ethics and pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Pharmacogenomics research involving racial classification: qualitative research findings on researchers' views, perceptions and attitudes towards socioethical responsibilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Risk assessment and communication tools for genotype associations with multifactorial phenotypes: the concept of "edge effect" and cultivating an ethical bridge between omics innovations and society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Society and ethics - the genetics of disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Tailored medicine: whom will it fit? The ethics of patient and disease stratification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

The genetics revolution, economics, ethics, and insurance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Ethical, legal, and social implications of genomic medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Awareness survey of parties involved in pharmacogenomics in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Patients' and physicians' perspectives on pharmacogenetic testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

The pharmacogenomics of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Impact of apoE genotype on oxidative stress, inflammation and disease risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

No APOEepsilon4 effect on coronary heart disease risk in a cohort with low smoking prevalence: the Whitehall II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Metrifonate treatment of AD: influence of APOE genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Education may improve the underutilization of genetic services by Middle Eastern primary care practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Teaching and practicing pharmacogenomics: a complex matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Putting pharmacogenetics into practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03256401

Pharmacogenetics: ethical issues and policy options

21 January 2018

1 reference

12 December 2020

Bioethics for clinicians: 14. Ethics and genetics in medicine

1 reference

12 December 2020

Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies

1 reference

12 December 2020

Managing familial risk in genetic testing

1 reference

12 December 2020

Pharmacogenetic testing, informed consent and the problem of secondary information

1 reference

12 December 2020

Alzheimer's disease: genes, proteins, and therapy

1 reference

12 December 2020

Health Care Professionals' Perceptions of the Role of Pharmacogenomic Data

1 reference

12 December 2020

An ethical imperative: genetics education for physicians and patients.

1 reference

12 December 2020

The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies

1 reference

12 December 2020

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

1 reference

12 December 2020

Warfarin dosing and cytochrome P450 2C9 polymorphisms.

1 reference

12 December 2020

Comment on a view favoring ignorance of genetic information: confidentiality, autonomy, beneficence and the right not to know

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03256401

1 reference

24 August 2017

1 reference